Fernandez 1997.

Methods	RCT.
Participants	Inclusion criteria: singleton, non‐cephalic pregnancy; > 36 weeks' gestation. N = 103. Exclusion criteria: younger than 17 years of age, prior uterine surgery, ruptured membranes, placenta praevia, anomalous fetus, multiple gestation, sensitivity to terbutaline, other maternal medical complications.
Interventions	Intervention:tocolytic: terbutaline ‐ beta stimulant (A1) ‐ parenteral. Terbutaline 0.25 mg in unlabelled insulin syringe given SQ 15 to 30 minutes before ECV attempts. Forward then backward roll attempted. N = 52. Comparison:placebo. N = 51.
Outcomes	Successful ECV; CS.
Notes	Parkland Memorial Hospital, Dallas, Texas, USA. January 1994 to June 1995.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised computer tables ‐ randomisation by pharmacy using computer‐generated random sequence.
Allocation concealment (selection bias)	Unclear risk	No mention in article.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Terbutaline or placebo obtained from pharmacy in unlabelled syringe. Placebo was an equal volume of normal saline.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Placebo‐controlled trial with blinding of staff.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No exclusion of women or loss to follow‐up. Appears to be an intention‐to‐treat analysis.
Selective reporting (reporting bias)	Unclear risk	We did not assess the trial protocol.
Other bias	Low risk	With exception of maternal age, the 2 groups did not differ at baseline. Mean age for terbutaline group: 23.4. Mean age for placebo group: 25.7.